



MINUTES

Utah Department of Health
Drug Utilization Review Board

Thursday, November 9, 2017
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Keith Tolman, M.D., Board Chair
Jennifer Brinton, M.D.
Eric Cannon, Pharm.D., FAMCP
Neal Catalano, Pharm.D.
Aesha Drozdowski, Pharm.D.
Holly Gurgle, Pharm.D.
Steve Lore, M.D.

Kim Michelson, D.D.S.
Kumar Shah, M.Sc., P.Eng.
Susan Siegfried, M.D.
Katherine Smith, Pharm.D.
Sharon Weinstein, M.D.

Board Members Excused:

Ben Berrett, Pharm.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Sue Leong, RPh., Pharmacy Director
Andrea Rico, CPhT
Bryan Larson, Pharm.D., P&T Manager

Robyn Seely, Pharm.D., DUR Manager
Alyssa Pitts, R.N., P.A.
Merelynn Berrett, R.N., PA

University of Utah Drug Regimen Review Center Staff Presenter:

Joanita Lake, B.Pharm, MSc EBHC

Other Individuals Present:

Joanne LaFleur, University of Utah Drug Regimen Review Center (DRRC)
Valerie Gonzales, DRRC
Elena Martinez Alonso, DRRC
Charissa Anne, Johnson & Johnson

Meeting conducted by: Board Chair

- 1. Welcome:** Keith Tolman opened the meeting and announced a quorum.
- 2. Information:** Keith Tolman mentioned the recently approved 5 years of Children's Health Insurance Program (CHIP) funding, Food and Drug Administration (FDA) review of new drugs for the treatment of Alzheimer's Disease, a newly approved stem cell therapy and the expansion of the state of Maine's Medicaid program.
- 3. Review and Approval of October Minutes:** Kumar Shah suggested an "Information" section to be added to the typed minutes. Keith Tolman motioned to accept this suggestion. Jennifer Brinton seconded the motion. Unanimous approval. Kumar Shah

made a motion to Approve October's minutes. Sharon Weinstein seconded the motion. Unanimous approval.

4. **Housekeeping:** Sue Leong invited everyone to sign the rosters and Bryan Larson informed the Board of last month's Pharmacy and Therapeutics Committee meeting. Inhaled corticosteroids and beta-adrenergic agonists for the treatment of asthma were discussed. Sue Leong stated that Spinraza and Carbaglu would not be discussed at this Drug Utilization Review Board (DURB) meeting, but will be included in an upcoming discussion of orphan drugs.

5. **Pediatric Over-Use of Antibiotics discussion continued from October:**

- a. **Information:** Joanita Lake shared information gained from consulting with Adam Hersh MD, Pediatric Infectious Disease specialist, whose research involves antibiotic prescribing patterns and improvement of antibiotic use. Utah Medicaid antibiotic use for all ages was compared to Utah aggregate data (all payers) furnished by the Center for Disease Control (CDC). Special attention was given to fluoroquinolones.
 - b. **Public Comment:** Keith Tolman read aloud a letter submitted to the DURB by Andrew Pavia, MD, Chief of the Division of Pediatric Infectious Diseases.
 - c. **Board Discussion:** Kumar Shah discussed the importance of accurate information, so comparisons between Utah Medicaid and aggregate Utah data from the CDC are most useful. Eric Cannon discussed antibiotic resistance and relatively simple interventions other payers have taken which resulted in drastic decreases in resistance. Sharon Weinstein discussed the importance of public and practitioner education. Neal Catalano asked if it's possible to drill down and identify high-utilizing prescribers, then targeting those prescribers for education. Jennifer Brinton discussed changing guidelines that are not always followed by prescribers. Diagnosis codes were discussed, including accuracy issues. The DRRC can address this topic as part of their contracted work for the Department of Health. The DRRC will review claims data to identify high-utilizing prescribers (and specific patients if needed) and provide education to applicable prescribers. Keith Tolman mentioned efforts by the national Infectious Diseases Society to raise awareness of appropriate use of antibiotics, and Steve Lore agreed that their message seems to be understood.
 - d. **Board Action:** No motion was needed to give the above task to the DRRC, Medicaid can direct them to do the work as part of their standing contract.
6. **Suggestions for Future Meeting Topics:** Keith Tolman called for Board suggestions for future meeting topics. He suggested drugs for the treatment of psoriasis, of migraine, and of inflammatory bowel diseases. No motion is needed. Bryan Larson noted the suggestions and they are reflected in the written minutes. Sharon Weinstein noted that in the bylaws the Board's charge is to prevent fraud, waste, and abuse. Not every discussion or agenda item will result in a prior authorization.

7. **Public Meeting Adjourned:** Kumar Shah motioned to close the meeting. Eric Cannon seconded the motion. Unanimous Approval.
8. **The next meeting scheduled for** Thursday, December 14, 2017

Audio recordings of DUR meetings are available online at:
<https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/>